Phaseline

Companies › Visirna Therapeutics HK

Visirna Therapeutics HK: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Gastroenterology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VSA003
RNA interference (RNAi) therapeutic targeting ANGPTL3
ANGPTL3Phase 3Homozygous Familial Hypercholesterolemia (HoFH)Dec 2027
VSA006
siRNA targeting HSD17β13 mRNA to reduce HSD17β13 protein levels
HSD17B13Phase 2NashJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06322628VSA006Phase 2NashGastroenterologyJan 2027
NCT06712771VSA003Phase 3Homozygous Familial Hypercholesterolemia (HoFH)Metabolic and endocrineDec 2027

Targets

ANGPTL3 (1) HSD17B13 (1)

Companies with the same targets

Regeneron Pharmaceuticals Eddingpharm (Zhuhai) Verve Therapeutics Arrowhead Pharmaceuticals CRISPR Therapeutics

Companies built like this

Myungmoon Pharma. Eddingpharm (Zhuhai) Rivus Pharmaceuticals Eccogene Guangdong Raynovent Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.